REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07346547

Acronym

REDCURE

Enrollment

384

Registered

2026-01-16

Start date

2026-01-30

Completion date

2027-05-31

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD Anemia

Keywords

Daprodustat, oral HIF PHI, CKD anemia

Brief summary

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Interventions

DRUGDaprodustat

Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR) * Patients on hemodialysis (HD) or peritoneal dialysis (PD) * Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Exclusion criteria

1. Acute Kidney Injury (AKI) without underlying chronicity 2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia) 3. Refusal or inability to provide consent 4. Current enrollment in an interventional trial that restricts real-world data collection 5. Life expectancy \< 3 months, where follow-up is not feasible 6. Known contraindications to Daprodustat as per local prescribing information

Design outcomes

Primary

Measure	Time frame	Description
Serum hemoglobin levels	3 months	Hemoglobin response to therapy

Secondary

Measure	Time frame	Description
Frequency of MACE ( Major Adverse Cardiovascular Events)	3 months	MACE events: * Unstable angina requiring hospitalization * Non-fatal MI * Non-fatal stroke * Cardiovascular death * Other adverse events * Hospitalization episodes . Mortality * Optional patient-reported outcomes (fatigue, functional status)

Contacts

CONTACTHussain Abidi

NQmedicalaffairs@gmail.com+923322583236

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026